Endocrine Abstracts

Aim: A chemiluminescence enzyme immunoassay (CLEIA) for high-molecular-weight adiponectin (HMW-ADPN) was recently developed, and has been shown to be faster, more accurate and less expensive than conventional ELISA. In this study, we investigated the relationships between metabolic parameters and the HMW-ADPN level measured by CLEIA in a health check-up setting.

Methods: Informed consent was obtained from 1036 male and 416 female Japanese, 40 to 71 years of age, who participated in this study. Subjects receiving anti-diabetic medication or with suspected inflammation (serum CRP level > 1 mg/dl) were excluded from the analyses.

Results: Median levels of serum HMW-ADPN measured by CLEIA were 2.5 μg/ml in males and 4.95 μg/ml in females. The correlation with the levels measured by ELISA was very good (r=0.984, n=297). The serum HMW-ADPN level in males with metabolic syndrome (MetS) (2.13±1.14, n=173) was significantly lower than that in those without MetS (3.02±3.43, n=860, P < 0.0001). HMW-ADPN correlated positively with the serum HDL-cholesterol level in both males and females (r=0.41 and 0.38, respectively, P < 0.0001 for both), and inversely correlated with the BMI, waist circumference and triglycerides (r=−0.30 to −0.33, P < 0.0001 for all). HMW-ADPN correlated also with insulin resistance index (HOMA-IR) and serum CRP levels in both males and females (r=−0.33 and −0.28 in males, and r=−0.36 and −0.30 in females, P<0.0001 for all). Stepwise multiple regression analysis revealed the serum HMW-ADPN level to correlate independently with serum HDL-cholesterol, sex, HOMA-IR and CRP (F>20, P< 0.0001, R²=0.392).

Conclusions: These results suggest that measuring serum HMW-ADPN by CLEIA is useful, and that the serum HMW-ADPN level is closely correlated with parameters related to MetS and/or cardiovascular diseases.

Declaration of interest: I fully declare a conflict of interest. Details below:

Funding: This work was supported, however funding details unavailable.